M. Nooij

发表

Response shift in quality of life measurement in early-stage breast cancer patients undergoing radiotherapy

S. Jansen, A. Stiggelbout, M. Nooij, 2004, Quality of Life Research.

Improved diagnosis and treatment of soft tissue sarcoma patients after implementation of national guidelines: a population-based study.

M. Nooij, P. Krijnen, H. Gelderblom, 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile?

S. Jansen, A. Stiggelbout, M. Nooij, 2001, British Journal of Cancer.

Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863).

M. Piccart, T. Gorlia, M. Nooij, 2006, European journal of cancer.

Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup

M. van Glabbeke, M. Sydes, A. McTiernan, 2012, European journal of cancer.

"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808).

M. Nooij, R. Sylvester, L. Beex, 1991, European journal of cancer.

Survival of Patients with Ovarian Cancer due to a Mismatch Repair Defect

M. Nooij, G. Kenter, M. Janssen-Heijnen, 2005, Familial Cancer.

Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer.

M. Nooij, I. Vergote, D. Wagener, 2001, European Journal of Gynaecological Oncology.

Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup

R. Souhami, D. Machin, M. Nooij, 1997, The Lancet.

Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials.

M. van Glabbeke, M. Sydes, A. McTiernan, 2011, European journal of cancer.

First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group

M. Piccart, M. Nooij, R. Paridaens, 2004 .

Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group.

M. Nooij, J. Vermorken, G. Bolis, 2003, European journal of cancer.

Doxorubicin-paclitaxel - A safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European organization for research and treatment of cancer multicenter trial

M. Piccart, M. Nooij, D. Miles, 2003 .

Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.

M. van Glabbeke, J. Klijn, M. Nooij, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy--a phase II study of the EORTC Gynaecological Cancer Cooperative Group.

O. Dalesio, M. Nooij, J. Vermorken, 1994, European journal of cancer.

Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy

M. J. van de Vijver, S. Rodenhuis, P. Kristel, 2006, British Journal of Cancer.

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.

M. Piccart, M. Nooij, M. Franchi, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.

M. Piccart, M. Nooij, R. Paridaens, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer.

L Biganzoli, M. Piccart, M. Nooij, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: A European Osteosarcoma Intergroup study.

M. van Glabbeke, D. Machin, M. Nooij, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials.

L. Trani, M. van Glabbeke, M. Sydes, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.

S. Rodenhuis, M. Nooij, E. D. de Vries, 2003, The New England journal of medicine.

Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.

M. van Glabbeke, M. Sydes, M. Nooij, 2007, Journal of the National Cancer Institute.

A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma

R. Souhami, M. Nooij, M. Glabbeke, 1999 .

A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI).

M. van Glabbeke, R. Souhami, D. Machin, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. clinical outcomes and oncologists' preferences.

J. Klijn, J. de Haes, M. Nooij, 2003, European journal of cancer.

Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study.

M. Nooij, M. Glabbeke, A. Craft, 2005, European journal of cancer.

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.

M. Piccart, M. Nooij, R. Paridaens, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study

M. Piccart, M. Nooij, M. Namer, 2001, Anti-cancer drugs.

Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control.

M. Piccart, M. Nooij, R. Paridaens, 2000, Clinical breast cancer.

The effect of individually assessed preference weights on the relationship between holistic utilities and nonpreference-based assessment

S. Jansen, A. Stiggelbout, M. Nooij, 2004, Quality of Life Research.

Stability of Patients’ Preferences for Chemotherapy

S. Jansen, A. Stiggelbout, M. Nooij, 2001, Medical decision making : an international journal of the Society for Medical Decision Making.

Unstable Preferences:

S. Jansen, A. Stiggelbout, M. Nooij, 2000, Medical decision making : an international journal of the Society for Medical Decision Making.

Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients

Marie-Christine W. Gast, S. Rodenhuis, P. Span, 2008, BMC Cancer.

Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer.

M. J. van de Vijver, J. Peterse, S. Rodenhuis, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients

S. Rodenhuis, H. Boezen, M. Nooij, 2008, Bone Marrow Transplantation.

347 Steroids do reduce the severity and delay the onset of docetaxel (DXT) induced fluid retention: Final results of a randomized trial of the EORTC investigational drug branch for breast cancer (IDBBC)

J. Klijn, M. Piccart, M. Nooij, 1995 .

Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer : Update of the Dutch randomized

S. Rodenhuis, M. Nooij, D. Richel, 2005 .

Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial

S. Rodenhuis, M. Nooij, E. Wall, 2005, Breast Cancer Research.

Exemestane (Aromasin) is active and well tolerated as first-line hormonal therapy (HT) of metastatic breast cancer (MBC) patients (pts): results of a randomized phase II trial

M. Piccart, M. Nooij, R. Paridaens, 2000 .

Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer.

M. Nooij, M. Namer, I. Vergote, 2001, Gynecologic oncology.

[Adjuvant systemic therapy for patients with resectable breast cancer: guideline from the Dutch National Breast Cancer Platform and the Dutch Society for Medical Oncology].

M. Nooij, D. Richel, L. Beex, 2000, Nederlands tijdschrift voor geneeskunde.

Doxorubicin/paclitaxel

M. Piccart, M. Nooij, L. Duchateau, 2023, Reactions Weekly.

Survival after recurrent osteosarcoma: Data from three European Osteosarcoma Intergroup (EOI) randomized controlled

M. Sydes, M. Nooij, R. Morgan, 2008 .

Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study.

S. Rodenhuis, M. Nooij, C. Seynaeve, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.

M. Piccart, M. Nooij, L. Beex, 2002, European journal of cancer.

First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group.

M. Piccart, M. Nooij, R. Paridaens, 2004, Journal of Clinical Oncology.

Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life.

W. M. Smit, S. Rodenhuis, N. Aaronson, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose chemotherapy in breast cancer. The Dutch trial

S. Rodenhuis, O. Dalesio, M. Nooij, 2001 .

Doxorubicin‐paclitaxel

M. Piccart, M. Nooij, L. Duchateau, 2003, Cancer.

Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas.

M. J. van de Vijver, P. Kristel, M. Nooij, 2004, European journal of cancer.

Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life.

W. M. Smit, S. Rodenhuis, N. Aaronson, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diabetes insipidus and adrenal insufficiency in a patient with metastatic breast cancer.

M. Nooij, J. Nortier, T. Netelenbos, 2006, The Netherlands journal of medicine.